Further Decision Processed by IB
04/26/2025
Back to search
Official data from USPTO
RENMICE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
04/27/2025
Trademark type
Word
Nice classes
5
Filing date
10/20/2021
Registration date
09/03/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/03/2024
Last transaction
04/27/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
CN
Examiner
KEAM,ALEX S
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Representatives
Karen Feisthamel KDB Firm PLLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicines for human purposes for the treatment of tumorsinfectious diseasesinflammation and autoimmune diseases; diagnostic preparations for medical and veterinary purposes; biological preparations for medical purposes for the treatment of tumorsinfectious diseasesinflammation and autoimmune diseases; active pharmaceutical ingredientsantibodies for the treatment of human and animal diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of cancer; biochemical medicines for the treatment of tumorsinfectious diseasesinflammation and autoimmune diseases; vaccines; dietetic preparations adapted for medical use; medicines for veterinary purposes for the treatment of tumorsinfectious diseasesinflammation and autoimmune diseases
Publications
History of USPTO decisions and trademark events.
41 publications found
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
02/15/2025
XXCR
GENERIC MADRID TRANSACTION CREATED
02/15/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/03/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/03/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
09/03/2024
GPNX
NOTIFICATION PROCESSED BY IB
07/20/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/18/2024
PUBO
PUBLISHED FOR OPPOSITION
06/18/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/11/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
06/11/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/29/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/15/2024
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
04/02/2024
GPRA
PRIORITY ACTION E-MAILED
04/02/2024
CPRA
PRIORITY ACTION WRITTEN
04/02/2024
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
03/25/2024
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
09/21/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
06/12/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/24/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
05/24/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/28/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
03/24/2023
GNSL
LETTER OF SUSPENSION E-MAILED
03/24/2023
CNSL
SUSPENSION LETTER WRITTEN
03/24/2023
DPCC
DIVISIONAL PROCESSING COMPLETE
03/23/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
03/23/2023
DRRR
DIVISIONAL REQUEST RECEIVED
03/01/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/01/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/01/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/01/2023
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
03/01/2023
RFNT
REFUSAL PROCESSED BY IB
09/27/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/03/2022
RFRR
REFUSAL PROCESSED BY MPU
09/03/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/01/2022
CNRT
NON-FINAL ACTION WRITTEN
07/31/2022
DOCK
ASSIGNED TO EXAMINER
07/27/2022
MAFR
APPLICATION FILING RECEIPT MAILED
01/07/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/03/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/23/2021
Continuous trademark protection
Get notified about every new filing that threatens RENMICE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.